OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
4,76 USD
arrow_upward
+0,85%(+0,040) 1 D.
10-13, 16:00:00 GMT−4 · USD
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „OPHLY“ įžvalgos...
Atidaryti
4,78 USD
Aukšta
4,78 USD
Žema
4,76 USD
Rinkos kapitalizacija
1,13 trln.
Vid. kiekis
60,13 tūkst.
Apimtis
82,82 tūkst.
52 sav. aukšta
5,75 USD
52 sav. žema
3,81 USD
Beta
0,21
Neapmokėtos akcijos
1,50 mlrd.
Darbuotojų skaičius
4 tūkst.
Atidaryti
4,78 USD
Aukšta
4,78 USD
Žema
4,76 USD
Rinkos kapitalizacija
1,13 trln.
Vid. kiekis
60,13 tūkst.
Apimtis
82,82 tūkst.
52 sav. aukšta
5,75 USD
52 sav. žema
3,81 USD
Beta
0,21
Neapmokėtos akcijos
1,50 mlrd.
Darbuotojų skaičius
4 tūkst.
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
vz.lt
·
prieš 1 dieną
JAV rinkų apžvalga: prieš rezultatų skelbimo sezoną Volstrite nuotaikos nevienodos
RealClearMarkets
·
prieš 29 minutes
The Bigger Meaning of Italian Prosperity on Wall St
MarketBeat
·
prieš 11 minučių
Medline (NASDAQ:MDLN) Stock Has Average Target Price of $46.81
Seeking Alpha
·
prieš 1 valandą
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profilis
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Apie „Ono Pharmaceutical ADR Representing 1/3rd Ord Shs“
Generalinis direktoriusGyo Sagara | Gyo Sagara
Darbuotojai4,21 tūkst.
Įkurta1717
Pagrindinė būstinėOsaka, Osakos prefektūra, Japonija
Sektorius-
Svetainėono-pharma.com